ALL-TRANS RETINOIC ACID PLUS HIGH-DOSE DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED ITP
The combination of all-trans retinoic acid and high-dose dexamethasone was found to be a safe and active first-line therapy for patients with newly diagnosed immune thrombocytopenia. With few and mild side-effects at 6 months, all-trans retinoic acid plus high-dose dexamethasone resulted in a higher sustained response rate, a lower risk of clinically significant bleeding, and improved health-related quality of life, compared with high-dose dexamethasone alone… Read more
COMBINATION REGIMEN EFFECTIVE IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA
For patients with relapsed/refractory classical Hodgkin Lymphoma, second-line therapy with pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin was found to be highly active. As this combination regimen also has an acceptable tolerability profile and is compatible with outpatient administration, it is a promising option to efficiently bridge patients to consolidation with high-dose therapy and autologous haematopoietic cell transplant… Read more
DARATUMUMAB MAINTENANCE THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MM WHO RECEIVED ASCT
Part 2 of the CASSIOPEIA study demonstrated the clinical benefit of daratumumab maintenance therapy compared with observation in patients with newly diagnosed multiple myeloma who received ASCT. Daratumumab maintenance every 8 weeks for 2 years significantly reduced the risk of disease progression or death and demonstrated low rates of discontinuation due to adverse events… Read more
LONG-TERM CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN THE JULIET TRIAL
In the primary analysis of the international phase II JULIET trial of tisagenlecleucel, the best overall response rate was 52% and the complete response rate was 40% in adult patients with relapsed or refractory aggressive B-cell lymphomas. Long-term clinical outcomes with a median follow-up of 40.3 months, now confirm the durable activity and manageable safety profile of tisagenlecleucel… Read more
CEBPA-BZIP MUTATIONS ARE ASSOCIATED WITH FAVOURABLE PROGNOSIS IN DE NOVO AML
A recent report from the Children’s Oncology Group reported that CCAAT enhancer–binding protein α (CEBPA) basic-region leucine zipper motif (bZip) domain mutations in patients with acute myeloid leukaemia are associated with favourable clinical outcomes, regardless of mono or bi-allelic status. However, co-occurring CSF3R and CEBPA mutations are associated with a high relapse rate and nullify the favourable prognostic impact of CEBPA mutations… Read more
Top
